Article
Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Mar 2013
Seong S J, Lim M, Sohn S K, Moon J H, Oh S-J, Kim B S, Ryoo H M, Chung J S, Joo Y D, Bang S M, Jung C W, Kim D H, Park S Y, Yoon S S, Kim I, Lee H G, Won J H, Min Y H, Cheong J W, Park J S, Eom K S, Hyun M S, Kim M K, Kim H, Park M R, Park J, Kim C S, Kim H J, Kim Y K, Park E K, Zang D Y, Jo D Y, Lee H W, Yoon Y-R
Abstract excerpt
BACKGROUND: This study explored the impact of genetic polymorphisms in cytochrome P450 (CYP) enzymes and transporters on the plasma trough concentration of imatinib mesylate (IM) and clinical response in chronic myeloid leukemia (CML). PATIENTS AND METHODS: In total, 82 patients with CML who had been administered 400 mg IM daily for over 6 months were genotyped for 11 single-nucleotide polymorphisms in nine genes...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.